An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.

Autor: Clarke LE; Myriad Genetic Laboratories, Inc, Salt Lake City, Utah., Flake DD 2nd; Myriad Genetics, Inc, Salt Lake City, Utah., Busam K; Memorial Sloan Kettering Cancer Center, New York, New York., Cockerell C; The University of Texas Southwestern Medical Center, Dallas, Texas., Helm K; Penn State Hershey Dermatology, Hershey, Pennsylvania., McNiff J; Yale Dermatopathology, New Haven, Connecticut., Reed J; CellNetix Pathology and Laboratories LLC, Seattle, Washington., Tschen J; St. Joseph Dermatopathology, Houston, Texas., Kim J; Department of Pathology, Stanford School of Medicine, Stanford, California., Barnhill R; Department of Pathology, University of California Los Angeles, Los Angeles, California., Elenitsas R; Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania., Prieto VG; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nelson J; Myriad Genetics, Inc, Salt Lake City, Utah., Kimbrell H; Myriad Genetic Laboratories, Inc, Salt Lake City, Utah., Kolquist KA; Myriad Genetic Laboratories, Inc, Salt Lake City, Utah., Brown KL; Myriad Genetics, Inc, Salt Lake City, Utah., Warf MB; Myriad Genetic Laboratories, Inc, Salt Lake City, Utah., Roa BB; Myriad Genetic Laboratories, Inc, Salt Lake City, Utah., Wenstrup RJ; Myriad Genetics, Inc, Salt Lake City, Utah.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2017 Feb 15; Vol. 123 (4), pp. 617-628. Date of Electronic Publication: 2016 Oct 21.
DOI: 10.1002/cncr.30385
Abstrakt: Background: Recently, a 23-gene signature was developed to produce a melanoma diagnostic score capable of differentiating malignant and benign melanocytic lesions. The primary objective of this study was to independently assess the ability of the gene signature to differentiate melanoma from benign nevi in clinically relevant lesions.
Methods: A set of 1400 melanocytic lesions was selected from samples prospectively submitted for gene expression testing at a clinical laboratory. Each sample was tested and subjected to an independent histopathologic evaluation by 3 experienced dermatopathologists. A primary diagnosis (benign or malignant) was assigned to each sample, and diagnostic concordance among the 3 dermatopathologists was required for inclusion in analyses. The sensitivity and specificity of the score in differentiating benign and malignant melanocytic lesions were calculated to assess the association between the score and the pathologic diagnosis.
Results: The gene expression signature differentiated benign nevi from malignant melanoma with a sensitivity of 91.5% and a specificity of 92.5%.
Conclusions: These results reflect the performance of the gene signature in a diverse array of samples encountered in routine clinical practice. Cancer 2017;123:617-628. © 2016 American Cancer Society.
(© 2016 Myriad Genetics, Inc. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: